As President Obama prepares to release his U.S. AIDS strategy, at least one pharmaceutical company is readying a crucial clinical trial of its vaccine against HIV/AIDS.
Celgene Acquires Abraxis In $2.9 Billion Deal
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
OneMedForum to Highlight the Newest, Most Promising Med Tech Innovations
OneMedPlace announced that it will showcase to investors and entrepreneurs the newest and most promising new medical technologies in the region.
Father’s Day Draws Attention to Prostate Cancer
Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
Nanoparticles Could Be Tiny Cancer Assassins
One type of nanoparticle currently in development engages in “active targeting,” or targeting drugs to cancer cells by attaching them to a molecule that the cancer cell is receptive to.
Pressure BioSciences Presents Symposium On Applications of PCT Technology
On May 21, 2010 Pressure BioSciences, Inc. (NasdaqCM: PBIO) sponsored a symposium at Harvard Medical School on the “Applications of Ultra-High Pressure in Technology.”
Bypassing Gastric Bypass Surgery
A number of companies are developing minimally invasive devices that produce the weight-reducing effects of a gastric bypass minus the actual surgery.
Brain Cancer Vaccine Extends Survival Rate In Small Trial
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
